Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction.

The research article investigates whether the expression of activation-dependent surface markers in horse platelets is influenced by phospodiesterase (PDE) enzyme activity, and if antigen challenge alters PDE activity in horses suffering from recurrent airway obstruction (RAO). The results indicate that PDE3 enzyme is a significant regulator of equine platelet activation, and altered regulation of PDE5 enzyme might contribute to an antigen-induced response in horses afflicted by RAO.

Methodology

The study used 16 horses in total:

• Seven healthy horses were employed in in vitro tests.
• Six horses with RAO were utilized for antigen challenge experiments.
• Six healthy horses were used as control animals, among which there were three horses that had been part of the in vitro experiments as well.

The effects of PDE inhibition and adenylyl cyclase activation on the expression of CD41/61 and CD62P on platelets, and on the formation of platelet-neutrophil aggregates in vitro, were studied through flow cytometry. Additionally, platelet PDE activity and its sensitivity to inhibition of PDE3 and PDE5 isoenzymes were evaluated in both RAO-infected horses and control horses, before and after antigen challenge.

Results

The results found that inhibition of PDE or activation of adenylyl cyclase considerably obstructed stimulus-induced expression of CD41/61 and CD62P, and also reduced the percentage of CD62P positive cells. Among PDE inhibitors, only trequinsin (a PDE3 inhibitor) significantly reduced the formation of platelet-neutrophil aggregates.

Moreover, it was observed that platelet PDE activity decreased after antigen challenge in both RAO-affected as well as control horses. Specifically in the case of horses suffering from RAO, there was a significant increase in the sensitivity of platelet PDE to inhibition by zaprinast (a PDE5 inhibitor) after 5 hours.

Conclusions

The findings of the study lend additional support to the concept that PDE3 is a key player in regulating equine platelet activation. It also suggests that a shift in the regulation of PDE5 could be a contributing factor to the antigen-induced response in horses with RAO. This research could potentially lead to more targeted therapeutic approaches to treating horses with RAO.